ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2019

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.

H H Yoon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.